건강 보험 청구 자료를 이용한 COPD 환자에서 치료제 처방 변화 분석: 흡입제를 중심으로 (Analysis of Treatment Pattern in COPD Patients Using Health Insurance Claims Data: Focusing on Inhaled Medications)

서지정보

· 발행기관 : 한국임상약학회
· 수록지 정보 : 한국임상약학회지 / 32권 / 3호 / 155 ~ 165페이지
· 저자명 : 임하나, 박미혜

초록

Background: Chronic obstructive pulmonary disease (COPD) is not completely reversible and requires long-term management withappropriate treatment. This study aimed to analyze trends in treatment regimens and medication costs for COPD patients using anational claims database. Methods: We conducted this analysis using National Patient Sample data from the Health InsuranceReview and Assessment Service covering the period from 2015 to 2018. We have constructed a dataset comprising COPD diseaseclassification codes J43.x and J44.x (based on KCD-7 code, J43.0 was excluded) and compiled a list of drugs fitting currentguidelines. To identify trends, we calculated frequency, ratio, and compound annual growth rate (CAGR) using the numbers ofprescriptions and patients. Results: The number of COPD patients was 7,260 in 2018, slightly decreased from 2015. Most of theseCOPD patients were aged 60 or older and included a high proportion of males (72.2%; 2018). The number of patients prescribedinhaled medications increased gradually from 2015 to 2018 (9,227 (47.1%); 2015, 9,285 (51.5%); 2018), while the number ofpatients prescribed systemic beta-agonists and Xanthines has decreased since 2015 (CAGR −14.7; systemic beta-agonist, −5.8;Xanthines). The per capita cost of medication has increased by 0.4% (KRW 206,667; 2018, KRW 204,278; 2015) annually duringthe study period. Conclusion: This study showed that treatment with inhaled medications had continuously increased in accord withchanging guidelines, but oral medications were still widely used. It is necessary to emphasize the importance of inhaled medicationsin treating COPD to reduce additional economic burden through appropriate medication use.

영어초록

Background: Chronic obstructive pulmonary disease (COPD) is not completely reversible and requires long-term management withappropriate treatment. This study aimed to analyze trends in treatment regimens and medication costs for COPD patients using anational claims database. Methods: We conducted this analysis using National Patient Sample data from the Health InsuranceReview and Assessment Service covering the period from 2015 to 2018. We have constructed a dataset comprising COPD diseaseclassification codes J43.x and J44.x (based on KCD-7 code, J43.0 was excluded) and compiled a list of drugs fitting currentguidelines. To identify trends, we calculated frequency, ratio, and compound annual growth rate (CAGR) using the numbers ofprescriptions and patients. Results: The number of COPD patients was 7,260 in 2018, slightly decreased from 2015. Most of theseCOPD patients were aged 60 or older and included a high proportion of males (72.2%; 2018). The number of patients prescribedinhaled medications increased gradually from 2015 to 2018 (9,227 (47.1%); 2015, 9,285 (51.5%); 2018), while the number ofpatients prescribed systemic beta-agonists and Xanthines has decreased since 2015 (CAGR −14.7; systemic beta-agonist, −5.8;Xanthines). The per capita cost of medication has increased by 0.4% (KRW 206,667; 2018, KRW 204,278; 2015) annually duringthe study period. Conclusion: This study showed that treatment with inhaled medications had continuously increased in accord withchanging guidelines, but oral medications were still widely used. It is necessary to emphasize the importance of inhaled medicationsin treating COPD to reduce additional economic burden through appropriate medication use.

참고자료

· 없음